| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/05/2011 | US20110104263 Claudin-4 binding peptides, compositions and methods of use |
| 05/05/2011 | US20110104262 Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent |
| 05/05/2011 | US20110104261 Remote detection of substance delivery to cells |
| 05/05/2011 | US20110104260 Vaccine against varicella zoster virus |
| 05/05/2011 | US20110104259 Processes for taste-masking of inhaled formulations |
| 05/05/2011 | US20110104258 Technique for drug and gene delivery to the cell cytosol |
| 05/05/2011 | US20110104257 Polymorphisms predictive of platinum-coordinating compound-induced ototoxicity |
| 05/05/2011 | US20110104256 Methods for treating or preventing colorectal cancer |
| 05/05/2011 | US20110104255 Therapeutic agent for fibroid lung |
| 05/05/2011 | US20110104254 Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells |
| 05/05/2011 | US20110104253 Agent for intra-articular injection |
| 05/05/2011 | US20110104252 Anti-apoptotic gene scc-s2 and diagnostic and therapeutic uses thereof |
| 05/05/2011 | US20110104251 Cosmetic Composition And Method For Retarding Hair Growth |
| 05/05/2011 | US20110104250 Redox-gated Liposomes |
| 05/05/2011 | US20110104249 Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters |
| 05/05/2011 | US20110104248 Liposomes and immunopotentiating compositions containing the same |
| 05/05/2011 | US20110104247 Composition for stabilizing beta-blocker and transdermally absorbable preparation comprising the same |
| 05/05/2011 | US20110104246 Method of wound treatment using liquid gallium nitrate |
| 05/05/2011 | US20110104245 Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and adhesive resins, for medical application purposes |
| 05/05/2011 | US20110104244 Transdermal therapeutic system provided with improved long-term carrying comfort |
| 05/05/2011 | US20110104242 Cartilage material |
| 05/05/2011 | US20110104241 Percutaneous absorption enhancer and transdermal preparation using the same |
| 05/05/2011 | US20110104240 Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections |
| 05/05/2011 | US20110104239 Probiotic chewing gum method of manufacture |
| 05/05/2011 | US20110104238 Wettable fillers for improved release of hydrophilic materials from chewing gum compositions |
| 05/05/2011 | US20110104237 Bone strengthening food supplement |
| 05/05/2011 | US20110104236 Therapeutic compositions for treatment of ocular inflammatory disorders |
| 05/05/2011 | US20110104235 Compositions and methods for treating conditions of the nail unit |
| 05/05/2011 | US20110104234 Biodegradable Modified Carpolactone Polymers for Fabrication and Coating Medical Devices |
| 05/05/2011 | US20110104233 Flowable composition that sets to a substantially non-flowable state |
| 05/05/2011 | US20110104232 Sustained Release Systems of Ascorbic Acid Phosphate |
| 05/05/2011 | US20110104231 Bioceramic and biopolymer composite |
| 05/05/2011 | US20110104229 Bone Xenograft |
| 05/05/2011 | US20110104228 Self-eliminating coatings |
| 05/05/2011 | US20110104226 Peptides having binding affinity to an antibody which recognizes an epitope on an a1 loop 2 or beta2 loop 1 of an adrenoreceptor |
| 05/05/2011 | US20110104225 Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair |
| 05/05/2011 | US20110104219 Denture care composition |
| 05/05/2011 | US20110104218 Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity |
| 05/05/2011 | US20110104217 Bioactive Peptides and Method of Using Same |
| 05/05/2011 | US20110104216 Processes for the preparation of a batch of an active pharmaceutical ingredient, a container comprising cryogranules of an allergen product, and a cryogranule of an allergen product |
| 05/05/2011 | US20110104215 Transdermally absorbable preparation |
| 05/05/2011 | US20110104214 Once-a-day oxycodone formulations |
| 05/05/2011 | US20110104213 Porous Biomolecule-Containing Metal-Organic Frameworks |
| 05/05/2011 | US20110104212 Polymeric compositions with enhanced saline holding capacity and their method of preparation and use |
| 05/05/2011 | US20110104116 Hsa-free formulations of interferon-beta |
| 05/05/2011 | US20110104074 Methods for targeted cancer treatment and detection |
| 05/05/2011 | US20110104069 Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
| 05/05/2011 | US20110104052 Methods of synthesis and use of chemospheres |
| 05/05/2011 | US20110104051 Chemically Modified Viral Capsids as Targeted Delivery Vectors for Diagnostic and Therapeutic Agents |
| 05/05/2011 | US20110101240 Fluorescent ink compositions comprising functionalized fluorescent nanocrystals |
| 05/05/2011 | US20110100361 Pressurised metered dose inhalers (mdi) |
| 05/05/2011 | US20110100030 Processes for the preparation of a batch of an active pharmaceutical ingredient, a container comprising cryogranules of an allergen product, and a cryogranule of an allergen product |
| 05/05/2011 | CA2785687A1 Composition containing fesoterodine and fibers |
| 05/05/2011 | CA2779613A1 Apparatus and method for cryogranulating a pharmaceutical composition |
| 05/05/2011 | CA2779601A1 Vaccine compositions and methods of use |
| 05/05/2011 | CA2779577A1 Stabilized protein formulations and use thereof |
| 05/05/2011 | CA2779518A1 Gastroretentive oral high dose zinc preparations |
| 05/05/2011 | CA2779316A1 Paclitaxel/steroidal compound |
| 05/05/2011 | CA2779166A1 Submicro emulsion of paclitaxel using steroid complex as intermediate carrier |
| 05/05/2011 | CA2779111A1 Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis |
| 05/05/2011 | CA2779104A1 Ocular drug delivery devices |
| 05/05/2011 | CA2779099A1 Templated nanoconjugates |
| 05/05/2011 | CA2779096A1 Methods for treating parkinson's disease |
| 05/05/2011 | CA2778981A1 Solid dispersion of rifaximin |
| 05/05/2011 | CA2778689A1 Transdermal pharmaceutical compositions comprising active agents |
| 05/05/2011 | CA2777937A1 Solid pharmaceutical compositions containing an integrase inhibitor |
| 05/05/2011 | CA2777532A1 Stable rasagiline composition |
| 05/05/2011 | CA2777218A1 Fast dissolving solid dosage form |
| 05/05/2011 | CA2776925A1 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 05/05/2011 | CA2776723A1 Sterilization of biodegradable hydrogels |
| 05/04/2011 | EP2316935A1 Aptamer against il-17 and use thereof |
| 05/04/2011 | EP2316850A2 HASylated polypeptides, especially HASylated erythropoietin |
| 05/04/2011 | EP2316505A2 Mems device for delivery of therapeutic agents |
| 05/04/2011 | EP2316490A2 Methods and compositions for enhanced delivery of bioactive molecules |
| 05/04/2011 | EP2316482A1 Transcutaneous immunostimulation |
| 05/04/2011 | EP2316477A1 Immunogenic LHRH compositions and methods relating thereto |
| 05/04/2011 | EP2316473A1 Use of calcitonin in osteoarthritis |
| 05/04/2011 | EP2316472A1 Composition for transmucosal delivery of polypeptides |
| 05/04/2011 | EP2316471A1 Pharmaceutical formulations for sustained drug delivery |
| 05/04/2011 | EP2316460A1 Solution for peritoneal dialysis |
| 05/04/2011 | EP2316454A1 Dosage form containing pantoprazole as active ingredient |
| 05/04/2011 | EP2316449A1 Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| 05/04/2011 | EP2316448A1 An entacapone-containing oral dosage form |
| 05/04/2011 | EP2316442A1 Rapid dissolution formulation of a calcium receptor-active compound |
| 05/04/2011 | EP2316440A1 Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent |
| 05/04/2011 | EP2316439A1 Abuse resistant opioid containing transdermal systems |
| 05/04/2011 | EP2316438A1 Tape , in particular adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent |
| 05/04/2011 | EP2316437A1 Multilayer drug delivery system with barrier against reservoir material flow |
| 05/04/2011 | EP2316436A1 Tape, in particular adhesive tape, for the treatment of skin disorders comprising a film , in particular dissolvable film, containing at least one enzyme |
| 05/04/2011 | EP2316435A1 Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine |
| 05/04/2011 | EP2316434A1 Orally disintegrating tablets of memantine |
| 05/04/2011 | EP2316433A1 Orally disintegrating tablets of flurbiprofen |
| 05/04/2011 | EP2316432A1 Compound containing fesoterodine and roughage |
| 05/04/2011 | EP2316431A1 Solid oral composition comprising a S1P receptor agonist and a sugar alcohol |
| 05/04/2011 | EP2316430A1 Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| 05/04/2011 | EP2316429A1 Matrix for sustained, invariant and independent release of active compounds |
| 05/04/2011 | EP2316428A1 Matrix for sustained, invariant and independent release of active compounds |
| 05/04/2011 | EP2316427A1 Compositions and methods for improved delivery of hydrophobic therapeutic agents |
| 05/04/2011 | EP2316426A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 05/04/2011 | EP2316425A1 Liquid formulations comprising an active agent, glycerine and sorbitol |